Zacks Research Issues Negative Estimate for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Research analysts at Zacks Research cut their Q4 2024 earnings estimates for shares of Pacira BioSciences in a note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the company will earn $0.58 per share for the quarter, down from their prior estimate of $0.62. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.26 per share.

A number of other equities research analysts have also recently issued reports on the stock. Barclays lowered their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. StockNews.com lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Raymond James cut shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. reiterated an “underweight” rating and issued a $10.00 target price (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Finally, Jefferies Financial Group upped their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $17.81 on Monday. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $35.95. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm’s 50-day simple moving average is $16.53 and its two-hundred day simple moving average is $19.67. The firm has a market cap of $822.29 million, a price-to-earnings ratio of -8.77 and a beta of 0.82.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its position in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after buying an additional 932 shares in the last quarter. Park Place Capital Corp bought a new position in shares of Pacira BioSciences during the second quarter valued at approximately $46,000. Innealta Capital LLC purchased a new position in shares of Pacira BioSciences during the second quarter worth approximately $50,000. nVerses Capital LLC grew its stake in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares in the last quarter. Finally, CWM LLC increased its holdings in Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.